Hematology-Oncology Fact Sheet

We are living in a "golden age" for cancer research and discovery. Our knowledge and ability to have a direct impact on hematologic malignancies is increasing at a rapid pace, and patients are living longer thanks to advances in genetics, immunotherapy and precision medicine.

Our dedicated Syneos Health Hematology-Oncology team works continuously at the forefront of this rapidly advancing field, helping to improve treatment options around the world for patients who are desperately in need of better therapies for their hematologic malignancies.

We have worked on some of the most promising novel and emerging therapies in development, in indications ranging from non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to acute myeloid leukemia and multiple myeloma, and transitioning therapies from early phase to marketing authorization.

When it comes to hematology-oncology clinical development, we understand the importance of speed, agility and a dedicated focus on the development of novel precision therapies needed to treat sub-indications and address unmet medical needs. Our team has the right experience to support you in understanding how to quickly progress your treatment and see a faster agency approval. At Syneos Health, we see every clinical trial as an opportunity to shorten the distance from lab to life.

ファクトシートのダウンロード